Vetera-DDW-25

HYD LLC is a Hungarian biotechnology company specializing in the research and development of deuterium depletion technology for pharmaceutical and consumer health applications. The company is best known for its flagship product, Vetera-DDW-25, which is a registered veterinary anti-tumor medicine used to treat various cancers in small animals. Founded in 1993, HYD focuses on the biological significance of naturally occurring deuterium and its role in cell signaling and tumor growth. In addition to its veterinary line, the company produces the Preventa series of deuterium-depleted drinking water for human consumption and cancer prevention. HYD also conducts clinical research through its subsidiary, HYD Pharma, investigating deuterium-depleted water as an adjuvant therapy for human indications such as chronic lymphocytic leukemia and prostate cancer. The company's platform is based on the observation that reducing deuterium levels can inhibit oncogene expression and induce apoptosis in malignant cells.